Quarterly ResultMay 13, 2026, 04:12 PM
Spero Therapeutics Q1 Net Loss Halved to $7.2M; Operating Cash Flow Positive
AI Summary
Spero Therapeutics reported a significantly reduced net loss of $7.2 million for Q1 2026, down from $13.9 million in Q1 2025, and achieved positive operating cash flow of $15.9 million. The company has ceased development of its SPR206 and SPR720 programs, focusing resources on the tebipenem HBr program, for which GSK submitted an NDA with a PDUFA date of June 18, 2026. Despite a decrease in total revenue, operating expenses were substantially lower due to the strategic reprioritization.
Key Highlights
- Q1 2026 net loss decreased to $7.2 million from $13.9 million in Q1 2025.
- Net loss per share improved to $(0.13) in Q1 2026 from $(0.25) in Q1 2025.
- Net cash provided by operating activities was $15.9 million in Q1 2026.
- Total revenues for Q1 2026 were $0.3 million, down from $5.9 million in Q1 2025.
- Research and development expenses decreased to $2.9 million from $13.6 million.
- General and administrative expenses decreased to $4.9 million from $6.8 million.
- PDUFA date for tebipenem HBr is set for June 18, 2026.
- Ceased SPR206 (March 2025) and SPR720 (November 2025) development programs.
Price Impact
More from SPRO